Company Profile

Oxalo Therapeutics Inc
Profile last edited on: 9/26/2019      CAGE: 81RX8      UEI: JD11RKB2KWJ3

Business Identifier: Drug to treat severe oxalate pathologies: rare renal diseases and prevention of recurrent kidney stones
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1452 East 53rd Stret Floor 2
Chicago, IL 60615
   (530) 848-3499
Location: Single
Congr. District: 02
County: Cook

Public Profile

With close ties to University of Chicago where some of the work on which the firm is based was undertaken and which institution also invested in start up of the firm. With the focus on treatment and prevention of kidney stones, Oxalo is structured to work with a drug that mimics a microbe found in the body that helps to prevent kidney stones by removing oxalate, the toxic molecule that, when combined with calcium, causes most kidney stones. The drug on which Oxalo is working treats primary and secondary hyperoxaluria, and resulting severe recurrent kidney stones. Using the University of Chicago breakthrough microbiome research, the firm directly targets the biology of these diseases and can uniquely utilize the orphan drug pathway in clinical trials.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NSF $1,224,994
Project Title: Developing a Novel Drug Delivery System to Enable an Oral Peptide Based Drug for Kidney Stones
2020 2 NIH $2,299,991
Project Title: Developing a Peptide-Based Oral Drug to Prevent Kidney Stones

Key People / Management

  Hatim Hassan -- Co-Founder

  Altayeb Alshaikh

  Donna Arvans

  Yang Zheng -- Co-Founder & COO